Cargando…

Therapeutic Targeting of TP53-mutated Acute Myeloid Leukemia by Inhibiting HIF-1α with Echinomycin

TP53 mutation in acute myeloid leukemia (AML) is associated with poor prognosis. Since no targeted therapy is available to restore p53 function, it is of great interest to test whether other pathways activated by TP53 mutations can be therapeutically targeted. Here we showed HIF-1α target genes are...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Yin, Liu, Yan, Bailey, Christopher, Zhang, Huixia, He, Miao, Sun, Duxin, Zhang, Peng, Parkin, Brian, Baer, Maria R., Zheng, Pan, Malek, Sami N., Liu, Yang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7291851/ https://www.ncbi.nlm.nih.gov/pubmed/32060420 http://dx.doi.org/10.1038/s41388-020-1201-z

Ejemplares similares

The HIF1α-PDGFD-PDGFRα axis controls glioblastoma growth at normoxia/mild-hypoxia and confers sensitivity to targeted therapy by echinomycin
por: Peng, Gong, et al.
Publicado: (2021)

HIF-1α inhibitor echinomycin reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect
por: Yao, Yushi, et al.
Publicado: (2017)

TP53-Mutated Myelodysplasia and Acute Myeloid Leukemia
por: Testa, Ugo, et al.
Publicado: (2023)

Echinomycin inhibits adipogenesis in 3T3-L1 cells in a HIF-independent manner
por: Yamaguchi, Junna, et al.
Publicado: (2017)

Functional Classification of TP53 Mutations in Acute Myeloid Leukemia
por: Dutta, Sayantanee, et al.
Publicado: (2020)

TP53 Alterations in Myelodysplastic Syndromes and Acute Myeloid Leukemia
por: Rahmé, Ramy, et al.
Publicado: (2023)

TP-0903 Is Active in Preclinical Models of Acute Myeloid Leukemia with TP53 Mutation/Deletion
por: Eisenmann, Eric D., et al.
Publicado: (2022)

Preexisting TP53 mutation in therapy-related acute myeloid leukemia
por: Schulz, Eduard, et al.
Publicado: (2014)

Clinical implications of subclonal TP53 mutations in acute myeloid leukemia
por: Prochazka, Katharina T., et al.
Publicado: (2019)

TP53 in Acute Myeloid Leukemia: Molecular Aspects and Patterns of Mutation
por: George, Binsah, et al.
Publicado: (2021)

Comparison of acute myeloid leukemia and myelodysplastic syndromes with TP53 aberrations
por: Dutta, Sayantanee, et al.
Publicado: (2022)

TP53 Mutation in Acute Myeloid Leukemia: An Old Foe Revisited
por: Shin, Dong-Yeop
Publicado: (2023)

Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidine
por: Bories, Pierre, et al.
Publicado: (2020)

TP53 Mutations in Acute Myeloid Leukemia: Still a Daunting Challenge?
por: Molica, Matteo, et al.
Publicado: (2021)

TP53 mutation in newly diagnosed acute myeloid leukemia and myelodysplastic syndrome
por: Niparuck, Pimjai, et al.
Publicado: (2021)

Ascorbate Inhibits Proliferation and Promotes Myeloid Differentiation in TP53-Mutant Leukemia
por: Smith-Díaz, Carlos C., et al.
Publicado: (2021)

Personalized Medicine for TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia
por: Cluzeau, Thomas, et al.
Publicado: (2021)

Targeting TP53-Mutated Acute Myeloid Leukemia: Research and Clinical Developments
por: Granowicz, Eric M, et al.
Publicado: (2022)

Are We Moving the Needle for Patients with TP53-Mutated Acute Myeloid Leukemia?
por: Shallis, Rory M., et al.
Publicado: (2022)

Rare Presentation of Acute Myeloid Leukemia With TP53 Mutation and Dermatologic Manifestations
por: Lott, Ronald, et al.
Publicado: (2023)

Activating STING1-dependent immune signaling in TP53 mutant and wild-type acute myeloid leukemia
por: Kogan, Aksinija A., et al.
Publicado: (2022)

Intronic SNPs of TP53 gene in chronic myeloid leukemia: Impact on drug response
por: Sailaja, K., et al.
Publicado: (2012)

TP53-mutant myelodysplastic syndrome and acute myeloid leukemia: the black hole of hematology
por: Patel, Shyam A., et al.
Publicado: (2022)

How I Treat TP53-Mutated Acute Myeloid Leukemia and Myelodysplastic Syndromes
por: Loschi, Michael, et al.
Publicado: (2022)

HIF-1α is over-expressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia
por: Griggio, Valentina, et al.
Publicado: (2020)

The Molecular Role of HIF1α Is Elucidated in Chronic Myeloid Leukemia
por: Singh, Vivek, et al.
Publicado: (2022)

Kevetrin induces apoptosis in TP53 wild-type and mutant acute myeloid leukemia cells
por: Napolitano, Roberta, et al.
Publicado: (2020)

The Prognostic Value of TP53 Mutations in Adult Acute Myeloid Leukemia: A Meta-Analysis
por: Qin, Guoxiang, et al.
Publicado: (2022)

Effects of echinomycin on endothelin-2 expression and ovulation in immature rats primed with gonadotropins
por: Wang, Zhengchao, et al.
Publicado: (2012)

TP53 inhibitor PFTα increases the sensitivity of arsenic trioxide in TP53 wildtype tumor cells
por: Wang, Haiwei, et al.
Publicado: (2022)

Genomic landscape of TP53-mutated myeloid malignancies
por: Abel, Haley J., et al.
Publicado: (2023)

Genomic landscape of TP53-mutated myeloid malignancies
por: Abel, Haley J., et al.
Publicado: (2023)

S127: DELTATP73 IMPOSES TP53 MUTANT-LIKE PHENOTYPES INCLUDING DRUG RESISTANCE AND POOR PROGNOSIS ON TP53-WILD TYPE ACUTE MYELOID LEUKEMIA.
por: Pereira-Martins, Diego A, et al.
Publicado: (2023)

Aptamer-functionalized pH-sensitive liposomes for a selective delivery of echinomycin into cancer cells
por: Lafi, Zainab, et al.
Publicado: (2021)

Somatic TP53 mutations are preleukemic events in acute lymphoblastic leukemia
por: Chitadze, Guranda, et al.
Publicado: (2023)

Echinomycin as a promising therapeutic agent against KSHV-related malignancies
por: Chen, Jungang, et al.
Publicado: (2023)

MDM4 Overexpressed in Acute Myeloid Leukemia Patients with Complex Karyotype and Wild-Type TP53
por: Li, Li, et al.
Publicado: (2014)

Additional cytogenetic features determine outcome in patients allografted for TP53 mutant acute myeloid leukemia
por: Loke, Justin, et al.
Publicado: (2022)

TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions
por: Daver, Naval G., et al.
Publicado: (2022)

HIF-transcribed p53 chaperones HIF-1α
por: Madan, Esha, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_1890tui53lucknc601ku3hlibr